Patients with METex14 skipping NSCLC were stratified by 1L and 2L+, and IRC-assessed objective response rate (ORR), PFS, and OS were compared….Tepotinib appeared to be associated with prolonged PFS and OS compared with capmatinib: median (m) PFS, 22.1 (11.3, not estimable [ne]) vs 12.1 months (8.3, ne); mOS, 29.7 (13.8, ne) vs 20.7 months (12.5, ne). In the matched 2L+ population, ORR by IRC in the weighted population for tepotinib was 50.1% (40.1, 60.1) compared with the GEOMETRY mono-1 Cohort 4 ORR of 40.6% (28.9, 53.1). Tepotinib also appeared to be associated with prolonged PFS and OS compared with capmatinib: mPFS, 11.5 (8.2, 16.8) vs 5.5 months (4.3, 8.3); mOS, 20.4 (17.0, 26.5) vs 13.7 months (8.9, 23.4)....The updated data from VISION improve the robustness of the MAIC analysis with capmatinib and confirm previous findings of prolonged PFS and OS favoring tepotinib.